New Drug Application (NDA)

New Drug Application (NDA)

Drafts an eCTD-compliant NDA demonstrating safety and efficacy for FDA submission under 21 CFR Part 314.

Prerequisites

1. Clinical trial data — Phase 1–3 protocols, CSRs, statistical analyses, patient demographics
2. CMC documentation — drug substance characterization, manufacturing process, batch records, stability data
3. Nonclinical study reports — pharmacology, toxicology (general, genetic, reproductive, carcinogenicity), safety pharmacology
4. PK/bioavailability data — human PK, special populations, DDI studies, exposure-response analyses
5. Regulatory correspondence — pre-IND/pre-NDA meeting minutes, special protocol assessments, FDA feedback
6. Proposed labeling drafts — if available
7. Patent and exclusivity information — patent numbers, expiration dates, exclusivity claims

Output Structure

Module 1: Administrative Information

Module 2: Summaries

2.5 Integrated Summary & Benefit-Risk

• Pharmacological class, MOA, therapeutic rationale
• Development program overview (nonclinical → Phase 1 → 2 → 3 logic)
• Pivotal trial summaries: design, population, endpoints, results (point estimates, CIs, p-values)
• Integrated safety: AE profile across program, SAEs, deaths, safety signals
• Risk mitigation: labeling, REMS if applicable
• Benefit-risk weighing per 21 CFR 314.50(c): efficacy magnitude vs. AE frequency/severity, disease seriousness, existing therapies

2.3 Quality Overall Summary (CMC)

2.4 Nonclinical Overview

All studies GLP-compliant per ICH M3(R2). Bridge nonclinical findings to clinical: starting dose selection, monitoring parameters, contraindications.

2.7 Clinical Summary

Pharmacokinetics: ADME profile — absorption (food effect, bioavailability), distribution (Vd, protein binding), metabolism (CYP isoforms, DDI potential), elimination (clearance, t½). Special populations: renal (mild→ESRD), hepatic (Child-Pugh A/B/C), elderly, pediatric, pharmacogenomics. Bioequivalence bridging if formulation changed. Exposure-response analysis → dosing justification.

Clinical Efficacy: Phase 1 (safety, PK, dose range) → Phase 2 (dose-ranging, dose selection rationale) → Phase 3 pivotal trials. For each pivotal trial: design/randomization/blinding, population (I/E criteria), primary + secondary endpoints, statistical plan (sample size, missing data, multiplicity), results with CIs and p-values, clinical meaningfulness. Include cross-trial consistency, subgroup analyses (age, sex, race, severity), and failed/negative trial explanations. Follow ICH E3 for CSR format.

Integrated Safety: Database size (total exposed, patient-years) vs. FDA adequacy guidance. Common AEs by SOC/PT (MedDRA) with dose-response. SAE narratives with causality. Death narratives (investigator + sponsor causality). Discontinuation rates. Lab shifts, vitals, ECG/QTc. Class-specific topics: hepatotoxicity (Hy's Law), immunogenicity (ADA), hypersensitivity, CV events, malignancies. Signal detection via disproportionality analysis.

Proposed Labeling (Module 1)

Draft per Physician Labeling Rule (21 CFR 201.56–57):

Include Medication Guide if serious public health concern; Instructions for Use if device component or complex administration.

Risk Management, Patent & Exclusivity, Environmental

• REMS (if applicable): goals, ETASU, implementation system, assessment timetable
• Patent: numbers, expiration dates, certifications; exclusivity claims (NCE 5 yr, orphan 7 yr, pediatric 6 mo)
• Environmental: claim categorical exclusion under 21 CFR 25.31; calculate EIC (max daily dose × annual patient population → aquatic concentration < 1 ppb); full EA if threshold exceeded

eCTD Assembly Checklist

• [ ] Module 1: Administrative, labeling, patent info
• [ ] Module 2: Summaries (quality, nonclinical, clinical)
• [ ] Module 3: Quality (CMC) full data
• [ ] Module 4: Nonclinical study reports
• [ ] Module 5: Clinical study reports
• [ ] Cross-references and hyperlinks between modules
• [ ] Consistent terminology throughout
• [ ] Proper eCTD file naming and metadata
• [ ] Gap analysis: flag missing data and strategic decision points

Guidelines

1. Trace conclusions to source data — never assert efficacy or safety without citing specific trial results or study findings
2. Anticipate FDA questions — proactively address data limitations, alternative interpretations, ambiguous precedents
3. Statistical rigor — include point estimates, CIs, p-values; distinguish statistical from clinical significance
4. Mark gaps explicitly — flag missing data with [DATA NEEDED: description]
5. Regulatory citations [VERIFY current versions]: 21 CFR Part 314, 21 CFR Parts 210/211, 21 CFR 201.56–57, 21 CFR 25.31/25.40, ICH Q1A, ICH E3, ICH M3(R2)
6. U.S. FDA jurisdiction only — do not extrapolate to EMA, PMDA, or other authorities unless instructed
7. Draft for sponsor review — mark areas requiring sponsor input, additional data, or strategic decisions before submission